Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR91 | A4D1P6 | 6/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 4/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14879488 | 0.81 | WDR91 (0.50) | WDR91CXCR3FAAHCCR1PTGS2 | |
| SCHEMBL16249347 | 0.79 | WDR91 (0.38) | WDR91CXCR3FAAHCCR1 | |
| SCHEMBL27995140 | 0.74 | DRD2 (0.31) | DRD2 | |
| SCHEMBL27995135 | 0.74 | WDR91 (0.45) | WDR91CXCR3FAAHCCR1PTGS2 | |
| SCHEMBL14879486 | 0.73 | WDR91 (0.38) | WDR91CXCR3FAAHCCR1POLB | |
| SCHEMBL14879485 | 0.72 | WDR91 (0.42) | WDR91CXCR3FAAHCCR1 | |
| SCHEMBL16249346 | 0.72 | WDR91 (0.53) | WDR91CXCR3CCR1PTGS2POLB | |
| SCHEMBL14897838 | 0.68 | OPRM1 (0.37) | CYP2C19POLB | |
| SCHEMBL14879602 | 0.68 | OPRM1 (0.34) | DRD2POLB | |
| SCHEMBL10207455 | 0.65 | CHRM2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2768491-B1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS INC (US) | 2016-12-21 | — | — | EP | disclosed |
| EP-2768491-B1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS INC (US) | 2016-12-21 | — | — | EP | disclosed |
| US-9266908-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2016-02-23 | — | — | US | disclosed |
| US-20140343019-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2014-11-20 | — | — | US | disclosed |
| US-20140343019-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2014-11-20 | — | — | US | disclosed |
| US-20140343019-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2014-11-20 | — | — | US | disclosed |
| EP-2768491-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | Mars, Incorporated (US) | 2014-08-27 | — | — | EP | disclosed |
| WO-2013059437-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED (US) | 2013-04-25 | — | — | WO | disclosed |
| WO-2013059437-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED (US) | 2013-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343019-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT1 | WDR91 975/4885CXCR3 1039/4885FAAH 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.